Literature DB >> 2703171

Importance of steroid receptors and aromatase activity in the prognosis of ovarian cancer: high tumor progesterone receptor levels correlate with longer survival.

B J Slotman1, R Kühnel, B R Rao, G H Dijkhuizen, J de Graaff, J G Stolk.   

Abstract

The presence of steroid receptors (82 tumors) and aromatase activity (39 tumors) in ovarian carcinomas was correlated with patient survival. No statistically significant correlation was found between the presence or absence of estrogen receptors (ER, 56.1%), progesterone receptors (PR, 57.3%), androgen receptors (AR, 91.5%), or aromatase activity (33.3%) and survival. However, high levels of PR were associated with better survival (P less than 0.05). Furthermore, there was a tendency for patients with advanced disease and PR-positive tumors to have better survival than those with advanced disease and PR-negative tumors (P = 0.13). Patients with tumors that did not contain any of the receptors and those in which ER and AR were absent, or in which PR and AR were absent, had poor survival. It is concluded that receptor status, especially of PR, may be of prognostic importance and that status of receptors and aromatase activity may become useful in selecting ovarian cancer patients for endocrine therapy.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2703171     DOI: 10.1016/0090-8258(89)90607-0

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  13 in total

1.  Detection of progesterone receptor forms A and B by immunohistochemical analysis.

Authors:  P A Mote; J F Johnston; T Manninen; P Tuohimaa; C L Clarke
Journal:  J Clin Pathol       Date:  2001-08       Impact factor: 3.411

2.  Androgen receptor protein levels are significantly reduced in serous ovarian carcinomas compared with benign or borderline disease but are not altered by cancer stage or metastatic progression.

Authors:  Miriam S Butler; Carmela Ricciardelli; Wayne D Tilley; Theresa E Hickey
Journal:  Horm Cancer       Date:  2013-02-27       Impact factor: 3.869

Review 3.  New insights on the role of hormonal therapy in ovarian cancer.

Authors:  Fiona Simpkins; Arlene Garcia-Soto; Joyce Slingerland
Journal:  Steroids       Date:  2013-02-08       Impact factor: 2.668

4.  Aromatase in human common epithelial ovarian neoplasms.

Authors:  K Kaga; H Sasano; N Harada; M Ozaki; S Sato; A Yajima
Journal:  Am J Pathol       Date:  1996-07       Impact factor: 4.307

5.  Molecular clustering based on ERα and EIG121 predicts survival in high-grade serous carcinoma of the ovary/peritoneum.

Authors:  Matthew P Schlumbrecht; Su-Su Xie; Gregory L Shipley; Diana L Urbauer; Russell R Broaddus
Journal:  Mod Pathol       Date:  2010-11-19       Impact factor: 7.842

6.  Expression and function of androgen receptor coactivator p44/Mep50/WDR77 in ovarian cancer.

Authors:  Martin Ligr; Ruzeen Rohintan Patwa; Garrett Daniels; Lorraine Pan; Xinyu Wu; Yirong Li; Liantian Tian; Zhenxing Wang; Ruliang Xu; Jingjing Wu; Fan Chen; Jinsong Liu; Jian-Jun Wei; Peng Lee
Journal:  PLoS One       Date:  2011-10-13       Impact factor: 3.240

7.  Progesterone receptor isoforms A and B in human epithelial ovarian carcinoma: immunohistochemical and RT-PCR studies.

Authors:  J Akahira; T Inoue; T Suzuki; K Ito; R Konno; S Sato; T Moriya; K Okamura; A Yajima; H Sasano
Journal:  Br J Cancer       Date:  2000-12       Impact factor: 7.640

8.  Inhibitory effects of aromatase inhibitor on estrogen receptor-alpha positive ovarian cancer in mice.

Authors:  Hachidai Hirakawa; Yoshihito Yokoyama; Hidemi Yoshida; Hideki Mizunuma
Journal:  J Ovarian Res       Date:  2014-01-10       Impact factor: 4.234

Review 9.  The Role of the Estrogen Pathway in the Tumor Microenvironment.

Authors:  Natalie J Rothenberger; Ashwin Somasundaram; Laura P Stabile
Journal:  Int J Mol Sci       Date:  2018-02-19       Impact factor: 5.923

10.  The role of hormonal factors and endocrine therapy in ovarian cancer.

Authors:  Krystyna Serkies; Marcin Sinacki; Jacek Jassem
Journal:  Contemp Oncol (Pozn)       Date:  2013-03-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.